Stocks · News reference
Dyne Therapeutics Stock Tumbles After Hours: Here's Why
Dyne Therapeutics stock fell after hours after pricing an upsized $375M public offering of common stock.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $47 to $45.
RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35
Dyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) Estimate
Why TJX Companies Stock Got Thrashed in August
TJX Companies' stock dropped nearly 15% in August despite solid Q2 2027 earnings with 5% revenue growth and 22% net income increase. The decline was driven by the company's full-year adjusted earnings guidance of $5.15-$5.20 per share falling short of analyst expectations of $5.22, combined with downgrades from Jefferies and Gordon Haskett analysts. The stock's prior strong performance had inflated valuations, making investors unforgiving of even modest misses on forward guidance.
Why Salesforce Stock Is Soaring This Week
Salesforce stock surged 22% this week after beating Q2 2027 earnings expectations with $11.35B in revenue versus $11.32B expected, and posting $4.29 diluted EPS versus $3.27 anticipated. The company raised its fiscal 2027 revenue guidance to $46.1-$46.4B and EPS guidance to $10.21-$10.25, prompting analysts to raise price targets. At 12.1x operating cash flow versus its five-year average of 18.3x, the stock is considered undervalued.